STATE-OF-THE-ART PAPER
Resistant HypertensionAn Overview of Evaluation and Treatment
Pantelis A. Sarafidis, MD, PhD* and
George L. Bakris, MD, FAHA, FASN ,*
* Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
Hypertensive Diseases Unit, Department of Medicine, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, Illinois
Manuscript received June 20, 2008;
revised manuscript received August 18, 2008,
accepted August 26, 2008.
* Reprint requests and correspondence: Dr. George L. Bakris, Hypertensive Diseases Unit, University of Chicago Pritzker School of Medicine, 5841 South Maryland Avenue, Chicago, Illinois 60637 (Email: gbakris{at}gmail.com).
Resistant hypertension is defined as failure to achieve goal blood pressure (BP) when a patient adheres to the maximum tolerated doses of 3 antihypertensive drugs including a diuretic. Although the exact prevalence of resistant hypertension is currently unknown, indirect evidence from population studies and clinical trials suggests that it is a relatively common clinical problem. The prevalence of resistant hypertension is projected to increase, owing to the aging population and increasing trends in obesity, sleep apnea, and chronic kidney disease. Management of resistant hypertension must begin with a careful evaluation of the patient to confirm the diagnosis and exclude factors associated with "pseudo-resistance," such as improper BP measurement technique, the white-coat effect, and poor patient adherence to life-style and/or antihypertensive medications. Education and reinforcement of life-style issues that affect BP, such as sodium restriction, reduction of alcohol intake, and weight loss if obese, are critical in treating resistant hypertension. Exclusion of preparations that contribute to true BP treatment resistance, such as nonsteroidal anti-inflammatory agents, cold preparations, and certain herbs, is also important. Lastly, BP control can only be achieved if an antihypertensive treatment regimen is used that focuses on the genesis of the hypertension. An example is volume overload, a common but unappreciated cause of treatment resistance. Use of the appropriate dose and type of diuretic provides a solution to overcome treatment resistance in this instance.
Key Words: resistant hypertension • management • evaluation • treatment
|
Abbreviations and Acronyms
| | ACE = angiotensin-converting enzyme | | ARB = angiotensin-receptor blocker | | BP = blood pressure | | CCB = calcium-channel blocker | | eGFR = estimated glomerular filtration rate | | ERA = endothelin-receptor antagonist | | NSAID = nonsteroidal anti-inflammatory drug | | RAS = renin-angiotensin system |
|
Related Article
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A36.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
R. Rossi, A. Nuzzo, D. Iaccarino, A. Lattanzi, G. Origliani, D. E. Monopoli, and M. G. Modena
Effects of antihypertensive treatment on endothelial function in postmenopausal hypertensive women. A significant role for aldosterone inhibition
Journal of Renin-Angiotensin-Aldosterone System,
December 1, 2011;
12(4):
446 - 455.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. D. Bisognano, G. Bakris, M. K. Nadim, L. Sanchez, A. A. Kroon, J. Schafer, P. W. de Leeuw, and D. A. Sica
Baroreflex Activation Therapy Lowers Blood Pressure in Patients With Resistant Hypertension: Results From the Double-Blind, Randomized, Placebo-Controlled Rheos Pivotal Trial
J. Am. Coll. Cardiol.,
August 9, 2011;
58(7):
765 - 773.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Symplicity HTN-1 Investigators
Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: Durability of Blood Pressure Reduction Out to 24 Months
Hypertension,
May 1, 2011;
57(5):
911 - 917.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Volpe and G. Tocci
Rethinking targets of blood pressure and guidelines for hypertension clinical management
Nephrol. Dial. Transplant.,
November 1, 2010;
25(11):
3465 - 3471.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Bakris, L. H. Lindholm, H. R. Black, H. Krum, S. Linas, J. V. Linseman, S. Arterburn, P. Sager, and M. Weber
Divergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial
Hypertension,
November 1, 2010;
56(5):
824 - 830.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
On behalf of the Canadian Hypertension Education P
2010 Canadian Hypertension Education Program recommendations: An annual update
Can Fam Physician,
July 1, 2010;
56(7):
649 - 653.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Tobin
Stable Angina Pectoris: What Does the Current Clinical Evidence Tell Us?
J Am Osteopath Assoc,
July 1, 2010;
110(7):
364 - 370.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Mancia, G. Parati, and A. Zanchetti
Electrical Carotid Baroreceptor Stimulation in Resistant Hypertension
Hypertension,
March 1, 2010;
55(3):
607 - 609.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. A. Maron and J. A. Leopold
Aldosterone Receptor Antagonists: Effective but Often Forgotten
Circulation,
February 23, 2010;
121(7):
934 - 939.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Ritz and A. Tomaschitz
Aldosterone, a vasculotoxic agent--novel functions for an old hormone
Nephrol. Dial. Transplant.,
August 1, 2009;
24(8):
2302 - 2305.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Kapoor and J. R. Kapoor
Blood Pressure Reduction With Potassium Supplementation
J. Am. Coll. Cardiol.,
March 31, 2009;
53(13):
1164 - 1164.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. A. Sarafidis and G. L. Bakris
Reply
J. Am. Coll. Cardiol.,
March 31, 2009;
53(13):
1164 - 1165.
[Full Text]
[PDF]
|
|
|
|
